The RUBY-3 Study: This clinical study is evaluating povetacicept, a new investigational drug, in people with IgA nephropathy (IgAN) and other autoimmune diseases of the kidney. Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys, thereby reducing or possibly reversing kidney damage.
All qualified patients who participate in RUBY-3 will receive povetacicept. Povetacicept is administered by injection once every four weeks. The study treatment period is six months, with the possibility of an optional six-month extension. Study sites are open and enrolling patients.
To participate in RUBY-3, you must:
- Be at least 18 years of age
- Live in the United States, South Korea, or Australia
- Have confirmed IgAN (IgA nephropathy)
- Currently have active disease despite receiving standard treatment(s).
Additional requirements apply. Our study doctors can help determine if you qualify
For more information including open study sites, please visit: https://clinicaltrials.gov/ct2/show/NCT05732402
